Meocil

Quick links to important sections

Meocil

Selected form

Method of action: Ophthalmologicals

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meocil

Quick Facts

Property Description
Active Ingredients Neomycin, Prednisolone Acetate, Sulfacetamide
Form Ophthalmic suspension or Ointment
Pharmacological Class Combination Anti-infective/Corticosteroid Agent
Route of Administration Topical Ophthalmic Route
Prescription Status Prescription-only medicine

What is Meocil and What Type of Medicine Is It?

Meocil is defined as a prescription-only, multi-component pharmaceutical preparation formulated exclusively for topical ophthalmic route administration. It is classified as a combination anti-infective/corticosteroid agent. This classification signifies that the product is a triple-action medication, integrating three distinct active ingredients to address complex ocular conditions. Meocil is a combination drug utilizing both synthetic and semi-synthetic derived compounds, a composition that is clinically recognized for its synergistic utility in treating ocular issues involving both infection and inflammation.


What Active Ingredients Does Meocil Contain?

Meocil contains a specific blend of three active compounds: Neomycin, Sulfacetamide, and Prednisolone Acetate, available as an ophthalmic suspension or an ophthalmic ointment. The formulation integrates two distinct antibacterial agents—Neomycin, an aminoglycoside antibiotic, and Sulfacetamide, a sulfonamide antibacterial agent—alongside Prednisolone Acetate, a potent glucocorticoid steroid. This combined action confirms the drug's unique utility in providing relief by both fighting infection and reducing swelling.


What is the General Purpose of This Combination Drug?

The general purpose of Meocil is to provide simultaneous antibacterial action and anti-inflammatory effect to control acute symptoms in the eye, such as those arising from bacterial conjunctivitis or blepharitis. The two antibacterial agents work together to address microbial proliferation, while the anti-inflammatory component rapidly diminishes the symptoms of the inflammatory cascade. This combined therapeutic approach, often recognized in clinical practice, is designed to effectively manage inflammatory eye states by targeting both the underlying source and the symptomatic tissue reaction.

Regulatory References

  1. NIH/NLM DailyMed Drug Labeling for Ophthalmic Combinations

What side effects are possible with Meocil?

Possible Side Effects and Safety Information

The safety profile of Meocil is documented through official government regulatory sources, which classify adverse reactions by frequency and System-Organ-Class (SOC). This information defines the known risks associated with the medicine.

Frequency-Classified Adverse Reactions

Side effects are categorized based on their documented occurrence in clinical trials:

Classification Examples of Reactions (SOC)
Very Common Nausea, Diarrhoea (Gastrointestinal)
Common Headache, Dizziness (Nervous system), Increased liver enzymes (Hepatobiliary), Abdominal pain (Gastrointestinal)
Uncommon Insomnia (Nervous system), Rash, Pruritus (Skin), Peripheral oedema (Vascular)
Rare Acute liver failure (Hepatobiliary), Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Angioedema (Skin)

Serious and Clinically Significant Reactions

Serious Adverse Reactions documented in regulatory labels include Acute liver failure and severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These rare events require immediate and permanent discontinuation of the medicine.

Safety data emphasizes the risk of hepatic enzyme elevation, which is most frequently observed within the first 8 weeks of therapy. Due to this risk, mandatory monitoring of liver function tests (ALT, AST) is required prior to and periodically during treatment.

Restrictions and Special Considerations

The medicine is contraindicated in patients with known hypersensitivity to the drug substance and those with severe pre-existing hepatic dysfunction. Use during pregnancy and breastfeeding is officially prohibited. Caution is also advised when administering to patients with severe renal impairment.

Overdose and Emergency Response

The official regulatory profile for Meocil (Neomycin, Prednisolone Acetate, Sulfacetamide ophthalmic) states that overdosage resulting from routine topical overuse is not ordinarily expected to cause acute problems. However, significant systemic toxicity may occur following accidental ingestion or excessive absorption, a scenario that mandates immediate medical attention.

The risk of overdose is primarily linked to the systemic effects of the Neomycin component, which can lead to life-threatening outcomes. Documented severe manifestations include respiratory paralysis due to neuromuscular blockade, and signs of irreversible organ damage such as nephrotoxicity and ototoxicity (e.g., permanent hearing loss). If signs of toxicity such as convulsions, difficulty breathing, or passing out are observed, governmental regulators require that individuals seek emergency medical attention or call emergency services (e.g., 911) immediately.

For accidental ingestion, initial response statements advise drinking fluids to dilute the substance. Management involves symptomatic and supportive treatment, often requiring close clinical observation and monitoring of renal function and auditory status. Patients with impaired renal function or of advanced age are officially documented as having a significantly greater risk of severe systemic toxicity following overdose exposure.

Therapeutic Uses of Meocil

What Meocil Treats: Main Uses and Benefits

Meocil is considered relevant in contexts involving inflammatory or irritative processes where a bacterial infection or risk of infection is present. This multi-component ophthalmic agent is applied across therapeutic domains where additional symptomatic support is needed, primarily to address symptom clusters that may become intense or disruptive.

Meocil is relevant for managing conditions that include bacterial conjunctivitis, infectious blepharitis, keratitis, and specific forms of chronic anterior uveitis. It is also applied in scenarios where additional management of discomfort is required, such as following eye surgery or irritation from chemicals and foreign objects.

“The combination of components is associated with symptomatic relief across key domains, supporting the management of both bacterial and inflammatory symptoms.”

This approach helps address symptoms linked to organ-specific functional stress, including redness, swelling, itching, and eye discharge. Symptomatic relief contributes to improved comfort and may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Symptom Support for Compounded Ocular Distress
Symptom Cluster Addressed Inflammation (Redness, Swelling, Burning) paired with Infection (Discharge, Pus)
Typical Context Acute external eye infections and scenarios involving temporary physiological imbalance (post-injury/post-surgical)
Patient Benefit Helps ease the overall symptom load during acute episodes

Eligibility and Restrictions for Use

Who Can and Cannot Use Meocil?

Meocil (Neomycin, Prednisolone Acetate, Sulfacetamide Ophthalmic) is a prescription medicine with specific eligibility rules determined by governmental regulatory agencies (such as the FDA) based on a patient’s age, allergy status, and pre-existing eye conditions.


Contraindications: Who Must Not Use Meocil

Use is absolutely prohibited if the patient meets any of the following criteria:

  • Allergy/Hypersensitivity: Known or suspected allergy to Sulfacetamide (a sulfa drug), Neomycin, Prednisolone Acetate, or any other ingredient in the product.
  • Active Viral Infections: Active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis, vaccinia, or varicella.
  • Other Serious Eye Infections: Active mycobacterial infection of the eye, fungal diseases of ocular structures, or acute untreated purulent ocular infections.

Eligibility and Restrictions

Population/Condition Eligibility Status or Limitation
Age (Under 6) Safety and efficacy have not been established for children younger than 6 years of age.
Pregnancy/Lactation Conditional use only if the potential benefit justifies the risk; requires clinical assessment.
Glaucoma Use requires caution and routine monitoring of Intraocular Pressure (IOP) if used for 10 days or longer.
Corneal Thinning Use requires caution due to the increased risk of corneal perforation.

What should I know about interactions with other medicines?

Meocil Interactions with other medicines and products

Meocil is a multi-component ophthalmic agent whose interaction profile is defined by chemical incompatibility, specific pharmacodynamic risks, and constraints related to administration timing. Given the topical ophthalmic route, the overall likelihood of systemic drug-drug interactions is considered minimal, but official labeling documents specific constraints.


Prohibited Combinations and Restrictions

Co-administration with silver preparations or silver solutions is strictly prohibited. This is due to a chemical incompatibility where the sulfacetamide component precipitates with silver salts, a restriction formally noted in regulatory prescribing information.

Interactions Affecting Risk and Exposure

  • The Prednisolone component may increase the anticoagulant activities of systemic drugs such as Warfarin or Acenocoumarol.
  • The Prednisolone component can also increase the risk of hypokalemia (low potassium) when used alongside potassium-depleting drugs like Amphotericin B.
  • The sulfacetamide component may increase the risk of methemoglobinemia if co-administered with certain local anesthetics, including Tetracaine.
  • Antacids, such as Aluminium Hydroxide, are documented to decrease the bioavailability and systemic exposure of the Prednisolone component.
  • Locally, the antibacterial efficacy of sulfacetamide may be reduced by Para-aminobenzoic acid (PABA), a substance found in purulent exudates.

Administration Timing Rules

A mandatory administration separation of at least 5 minutes is required when using Meocil with any other prescribed ophthalmic agents, including drops or ointments. This rule is documented in regulatory labeling to ensure proper contact time and absorption of all products.

Mechanism of Action

The mechanism of Meocil involves the simultaneous modulation of two core biological processes: the inhibition of microbial viability and the suppression of the local inflammatory response.


Dual-Point Attack on Bacterial Biosynthesis

Meocil employs two mechanistically distinct anti-infective agents to inhibit bacterial viability and growth. Neomycin exerts a bactericidal effect by binding to the 30S Ribosomal Subunit, which induces errors in protein synthesis that ultimately disrupt the bacterial cell structure. . Simultaneously, Sulfacetamide acts as a competitive inhibitor of the enzyme Dihydropteroate Synthase (DHPS), blocking the folic acid synthesis pathway essential for DNA precursor production and bacterial replication. This dual-mode cessation of key biosynthetic processes supports the reduction of microbial proliferation and cell viability.


Genomic Suppression of the Inflammatory Cascade

The anti-inflammatory mechanism relies on Prednisolone Acetate acting as an agonist for the intracellular Glucocorticoid Receptor (GR). This binding initiates a cascade of gene transrepression, which effectively shuts down the transcription of genes responsible for producing pro-inflammatory mediators such as cytokines and prostaglandins. This genomic-level modulation reduces capillary permeability and leukocyte migration, contributing to the physiological modulation of local tissue response and the adjustment of excessive signaling.

Dosage and Administration Information

Official Administration Guidelines

Meocil (Methylprednisolone Sodium Succinate) is typically administered by a healthcare professional in a clinical setting. The primary route of administration is through Intravenous (IV) injection or infusion for immediate effect, or via Intramuscular (IM) injection.

Dosing and Preparation

Initial dosing is highly variable and depends on the specific condition being treated, ranging from 10 mg to 500 mg IV. For specific acute, life-threatening conditions, a dose of 30 mg per kilogram of body weight may be used. The drug is supplied as a sterile powder and must be reconstituted using the specified diluent immediately before use. The solution must be visually inspected for any particles or discoloration prior to administration.

Administration Procedure

Meocil must be administered slowly. For doses up to 250 mg, the IV injection should take at least 5 minutes. For doses greater than 250 mg, or the 30 mg/kg dose, administration must be performed over a period of at least 30 minutes to mitigate procedural risks.

In pediatric patients, the dosage is based on the severity of the condition and clinical response, but the daily dose must not be less than 0.5 mg/kg. Subsequent doses and the final maintenance schedule are determined by the treating physician by gradually reducing the initial dose until the lowest effective level is reached. If you have concerns about a missed dose, you must immediately consult your prescribing healthcare provider.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Meocil

Research on combination ophthalmic agents like Meocil was studied for its use in short-term Randomized Controlled Trials (RCTs) to explore how symptoms change over time in conditions involving infection and inflammation. These studies primarily examined the agent's use in acute bacterial conjunctivitis and infectious blepharitis, conditions associated with acute or disruptive episodes.

In these trials, researchers primarily monitored outcomes related to physical discomfort and changes in the severity of clinical signs. Findings described patterns observed in the studies related to changes in measurements of signs like eye discharge and redness over short intervals, typically ranging from 5 to 14 days.

Evidence for Use in Chronic Conditions and Post-Surgical Care

The combination agent was examined in contexts involving chronic inflammatory conditions like anterior uveitis and in post-operative settings following eye surgery. These studies monitored measurements of inflammation severity, focusing on the anti-inflammatory component. For both uveitis and post-surgical care, the follow-up durations were limited, meaning that long-term effects are not fully established.

Research related to acute injury, such as corneal damage, consists mostly of observational studies and case reports. Due to the nature of acute trauma, certainty remains low when compared to RCTs for infection.

What Remains Uncertain About the Research Evidence

Key limitations include the fact that follow-up durations were limited across many pivotal trials, meaning the long-term control of conditions is not fully established. Comparative evidence is lacking for certain groups. When considering pediatric patients, data for certain groups remain insufficient, particularly for very young children. The specific therapeutic contribution of each of the three components is often inferred rather than being explicitly proven in dedicated trials.

Key Studies & References Therapeutic Class Review: Ophthalmic Antibiotic-Steroid Combinations - Texas Health and Human Services (HHS)

Frequently Asked Questions (FAQ)

Common questions about Meocil (FAQ)


Q: How does Meocil work in simple terms?

Official documents describe Meocil as a dual-action medicine. It contains a corticosteroid component which helps manage eye inflammation, such as redness and swelling. The drug also includes antibacterial agents that work by blocking the essential processes that susceptible bacteria need for growth and viability.


Q: Can older adults use Meocil?

Limited clinical data suggest that safety or effectiveness differences between older adults and younger patients are not consistently observed. However, specific regulatory studies focused exclusively on the geriatric population may be limited, and individual assessment by a healthcare provider is always necessary.


Q: How is Meocil different from a supplement?

Meocil is defined as a prescription-only pharmaceutical preparation. This means it contains chemically defined active ingredients that have been officially reviewed and approved by government agencies to address specific medical conditions, unlike a dietary supplement.


Q: What is the shelf life of Meocil tablets?

The product's shelf life extends until the expiration date printed on the original bottle or carton. Official documentation warns against using the medication if the solution or ointment has darkened in color, as this indicates instability.


Q: Why do some people stop using Meocil?

Official safety documentation specifies conditions that require immediate and permanent discontinuation. These include severe skin reactions (such as SJS or TEN), signs of acute liver failure, or persistent, new, or worsening eye pain or inflammation.


Q: Does the effectiveness of Meocil wear off over time?

Regulatory text does not discuss tolerance, but official warnings state that prolonged use of the corticosteroid component can lead to an increased risk of secondary infections and conditions like glaucoma. This potential for new complications is a risk associated with extended use.


Q: Do I have to take Meocil every day?

The typical regulatory-approved dosing schedule for the ophthalmic suspension involves multiple administrations per day, often spaced regularly throughout the waking hours and at bedtime. This schedule reflects the need for consistent administration during the course of therapy.


Q: Will Meocil show up on a drug test?

According to official regulatory schedules, the active ingredients in Meocil are not listed as controlled substances under the US Controlled Substances Act. Therefore, they are not typically included in standard drug screening tests.


Q: Is there a specific time of day that is best to take Meocil?

The official schedule emphasizes consistent, regular spacing of doses throughout the day to achieve the necessary therapeutic effect, rather than relying on one specific time of day.


Q: Is Meocil considered a controlled substance?

No, official regulatory classifications define Meocil as a prescription-only medicine. It is not listed as a controlled substance under the US Controlled Substances Act (CSA).


Q: How long am I typically expected to be on Meocil?

Meocil is described in official warnings as a treatment typically prescribed for short-term use. Use that extends beyond approximately 10 days is classified as prolonged use, which necessitates ongoing monitoring of eye pressure due to safety considerations.


Q: What should I do if a side effect of Meocil seems concerning?

Official patient counseling information advises patients to contact their healthcare provider immediately if eye inflammation or pain persists longer than 48 hours, worsens, or if any new symptoms arise.


Q: Can I drive while taking Meocil?

Regulatory patient information contains a warning that the medication may temporarily cause blurred vision upon instillation. Patients are advised to wait until their vision has fully cleared before driving or operating machinery.


Q: Does Meocil contain any common allergens like gluten or lactose?

The official label provides a list of all inactive ingredients within the product. While this list details chemical components, it does not typically contain direct statements about common food allergens like gluten or lactose.


Q: What is the purpose of the 'inactive ingredients' in Meocil?

The purpose of the inactive ingredients is described in regulatory filings. They are included to perform necessary functions such as ensuring the stability of the drug over time, maintaining the correct formulation (suspension or ointment), and preserving the product from contamination.


Q: Are there different strengths of Meocil available?

Official regulatory documents state that the combination product is available in different fixed concentrations, such as an ophthalmic suspension with specific percentages of the active ingredients, as well as an ophthalmic ointment form.


Q: What kind of specialist usually prescribes Meocil?

Initial prescribing and subsequent monitoring often require specialized examination of the eye using magnification tools, such as a slit lamp. This suggests that a specialized eye doctor, typically an ophthalmologist, is the healthcare provider responsible for prescribing and managing the treatment.


Q: Is there a generic version of Meocil available?

Yes, official regulatory information confirms that the combination of Sulfacetamide and Prednisolone is widely available as a generic option. Generic availability often means that lower-cost alternatives exist for the medicine.

How should Meocil be stored and disposed of?

How to Store and Dispose of Meocil?

The official storage and disposal requirements for Meocil (ophthalmic combination) are designed to maintain product stability and protect the environment.


Storage Requirements

Meocil must be kept at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). It is a mandatory instruction to keep the medication from freezing and to store it away from excess heat, moisture, and direct light in a tightly closed original container. If the ophthalmic solution appears darkened (e.g., yellowish-brown), it indicates instability and must not be used. All medication must be stored out of the sight and reach of children.


Disposal Instructions

Do not flush unused or expired Meocil down the toilet or pour it into a drain. Disposal should comply with official regulatory guidelines. The proper method involves utilizing a drug take-back program where available, or consulting a pharmacist for guidance on safe discarding methods for non-hazardous medication. Any unused portions should be discarded after the treatment course is completed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Meocil found in:

A-Z Index: